Bio Century. Managers, investors, scientists and regulators to manage the translation of science into medicine.
Bio Century. Managers, investors, scientists and regulators to manage the translation of science into medicine.
Today's Biocentury.com headlines: Observe fresh posts and updates on Bio Century. It is pretty active and updates frequently with 100+ articles published this month alone (they might potentially reach about 4.6K visitors within the said period of time). It is generally safe for browsing, so you may click any item to proceed to the site.
The French drug maker’s CEO Olivier Brandicourt once more showcased his deal discipline, but he could also do without pesky Americans snapping up his targets. By Paul Whitfield Sanofi SA’ CEO Olivier Brandicourt must be tiring of losing biotech targets...
Johnson & Johnson CEO Alex Gorsky will be sitting pretty as head of an even larger firm once the deal goes through On January 26, Johnson & Johnson, the world’s largest healthcare company, announced it will acquire Swiss pharmaceuticals and...
In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be...
London/New York: The Johnson & Johnson has approached Actelion Ltd about a potential takeover of the $17 billion Swiss drugmaker as the US health-care giant works to expand its pharmaceutical lineup, people familiar with the matter said. Deliberations...
Johnson & Johnson (No. 8 on the DiversityInc Top 50 Companies list) and Actelion Ltd. announced January 26 that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland...
True Engrossment of Reader is Real Profession of...
True Engrossment of Reader is Real Profession of a Writer.
SOCRATES is an international, refereed (peer-reviewed) and indexed scholarly hybrid open-access journal in Public Administration a...
Growth differentiation factor 15 (GDF15) - Molecular Target Profile - BioCentury – BCIQ
Comprehensive view of all products targeting Growth differentiation factor 15 (GDF15). Includes lead product status, indications and partnerships. Provides pipeline & competitive intelligence, market ...
Keytruda, pembrolizumab (MK-3475) - Product Profile - BioCentury
Comprehensive keytruda portfolio, including molecular targets, MOA, partnerships, milestones. Pipeline & competitive intelligence. Clinical & deal history. Market drivers & investment opportunities.
Essential business intelligence for biopharma executives, managers, investors, scientists and regulators to manage the translation of science into medicine.
28 years
Domain age
00:00:39
Visit duration
153
Daily visitors
80%
Bounce rate
N/A
Child safety
Good
Trust
Good
Privacy
86.7 %
USA